{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:28:46Z","timestamp":1793906926678,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmed.2026.108827","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:02:22Z","timestamp":1776697342000},"page":"108827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world impact of elexacaftor\/tezacaftor\/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4163-8783","authenticated-orcid":false,"given":"Razan","family":"Kharraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-7637","authenticated-orcid":false,"given":"Xiayi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshdeep","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zosia","family":"Gryz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0723-0898","authenticated-orcid":false,"given":"Allison","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-8876","authenticated-orcid":false,"given":"Jonathan H.","family":"Rayment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1785-3870","authenticated-orcid":false,"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-5653","authenticated-orcid":false,"given":"Anne L.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rmed.2026.108827_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"19","key":"10.1016\/j.rmed.2026.108827_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.rmed.2026.108827_bib3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2026.108827_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108827_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.rmed.2026.108827_bib6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/alr.23209","article-title":"Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy","volume":"13","author":"Tervo","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108827_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/alr.22700","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"11","author":"DiMango","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108827_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of PROMISE-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.108827_bib9","article-title":"Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis","volume":"49","author":"Silva Filho","year":"2024","journal-title":"J. Bras. Pneumol."},{"issue":"3","key":"10.1016\/j.rmed.2026.108827_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00289-2020","article-title":"Official ERS technical standard: Global lung function initiative reference values for static lung volumes in individuals of European ancestry","volume":"57","author":"Hall","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2026.108827_bib12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2026.108827_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(19)30723-4","article-title":"Validation of an electronic version of the cystic fibrosis quality of life evaluative self-administered test (eCF-QUEST)","volume":"18","author":"Tullis","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108827_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/lary.29766","article-title":"Development of sinonasal outcome test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps","volume":"132","author":"Khan","year":"2022","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.rmed.2026.108827_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/lary.27470","article-title":"Does medical therapy improve SinoNasal outcomes Test-22 domain scores? An analysis of clinically important differences","volume":"129","author":"Chowdhury","year":"2019","journal-title":"Laryngoscope"},{"issue":"9","key":"10.1016\/j.rmed.2026.108827_bib16","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/lary.31438","article-title":"Predictors of sinonasal improvement after highly effective modulator therapy in adults with cystic fibrosis","volume":"134","author":"Beswick","year":"2024","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.rmed.2026.108827_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2017.01.002","article-title":"Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher","volume":"16","author":"Szczesniak","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108827_bib18","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2026.108827_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.rmed.2026.108827_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/ph15050606","article-title":"Elexacaftor-tezacaftor-ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study","volume":"15","author":"Migliorisi","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.rmed.2026.108827_bib21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2026.108827_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharson","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108827_bib23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.rmed.2026.108827_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with elexacaftor-tezacaftor-ivacaftor in people with CF aged \u226512 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J. Cyst. Fibros."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:03:02Z","timestamp":1784934182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S0954611126001952"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108827","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of elexacaftor\/tezacaftor\/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108827"}}